Skip to main content
In stock|Immunotherapy (Investigational Checkpoint)

Acasunlimab

Oncology TypeSolid Tumour
Drug Class / MechanismBispecific Antibody, PD-L1 x 4-1BB Conditional Agonist
No Image
Description

Acasunlimab is classified as a Bispecific Antibody, PD-L1 x 4-1BB Conditional Agonist, sourced for use within our Immunotherapy (Investigational Checkpoint) portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic CategoryImmunotherapy (Investigational Checkpoint)
Oncology TypeSolid Tumour

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3